Autolus Therapeutics
AUTL
59 hedge funds and large institutions have $164M invested in Autolus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 20 closing their positions.
83% more call options, than puts
Call options by funds: $1.22M | Put options by funds: $665K
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
3% less capital invested
Capital invested by funds: $169M → $164M (-$5.08M)
3.64% less ownership
Funds ownership: 38.11% → 34.47% (-3.6%)
14% less funds holding
Funds holding: 69 → 59 (-10)
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$7.88M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$7.22M |
| 3 |
PG
Pendal Group
Sydney,
Australia
|
+$5.53M |
| 4 |
JP Morgan Chase
New York
|
+$3.79M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$698K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.12M |
| 2 |
SCM
Sio Capital Management
New York
|
-$3.93M |
| 3 |
Goldman Sachs
New York
|
-$3.75M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.59M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.27M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Barclays
London,
United Kingdom
| – | -$322 | -51 | -93% |
|
77
BNP Paribas Financial Markets
Paris,
France
| – | -$232 | -35 | Closed |
|
AUTL Hedge Fund Activity: Q3 2021 in Review
59 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2021, worth a combined $164M — down 3% from $169M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AUTL and 10 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 21 added.
The largest buyer was Frazier Management, adding an estimated $7.88M. The largest seller was Ikarian Capital, cutting an estimated $5.12M.
- 59 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2021, down from 69 in Q2 2021.
- Funds reported $164M of Autolus Therapeutics stock for Q3 2021, down 3% quarter-over-quarter.
- 10 funds opened new Autolus Therapeutics positions in Q3 2021 and 20 closed out, a net change of -10 holders.
- The largest Autolus Therapeutics buyer in Q3 2021 was Frazier Management, an estimated $7.88M added.
- The largest Autolus Therapeutics seller in Q3 2021 was Ikarian Capital, an estimated $5.12M sold.
Based on aggregated 13F filings for Q3 2021.